Interim report Perbio Science Ab January - September 2001

PRESS RELEASE, 25 October 2001 Interim report Perbio Science AB January-September 2001 Continued strong growth · Net sales up 36% to SEK 1 396 (1 029) million · Continued strong earnings growth at all divisions - Operating profit before amortisation of goodwill up 77% to SEK 260 (147) million - Profit after financial items but before amortisation of goodwill up 93% to SEK 253 (131) million - Profit after financial items up 106% to SEK 237 (115) million - Net profit up 107% to SEK 143 (69) million · Bioresearch division takes over sales of amidites (reagents for DNA synthesis) from Amersham Pharmacia Biotech · Construction of the Cell Culture division's new plant runs to schedule, with production due to start up in February 2002 - "Perbio Science recorded its best ever third-quarter sales and earnings, with net sales of SEK 500 million and net profit of SEK 51 million," says CEO Mats Fischier. - "Our operating margin for the first nine months was also 4.7 percentage points up on last year at 17.4%. - "Besides achieving strong earnings growth, Perbio has continued to increase its market share in the USA, launched more new products than in previous years and entered into several interesting alliances with customers and suppliers." - FURTHER INFORMATION For further information please contact CEO Mats Fischier (tel +46 42 26 90 91 or +46 70 595 18 21) or CFO Claes Wenthzel (tel +46 42 26 90 92 or +46 70 862 01 22). More information on Perbio Science can also be found on our website at www.perbio.com ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.waymaker.net/bitonline/2001/10/25/20011025BIT00270/bit0002.doc http://www.waymaker.net/bitonline/2001/10/25/20011025BIT00270/bit0002.pdf